newsfilter
← Latest News
GlobeNewswire·

Precipio Announces Q3-2026 Financial Results

  • Precipio, Inc. (NASDAQ: PRPO) announced third-quarter financial results for the period ending September 30, 2026.
  • Total revenue reached $7.3 million, an 8% increase year-over-year from $6.8 million in Q3-2025.
  • Product revenue was $1.0 million, up 40% year-over-year, while pathology revenue was $6.3 million, up 5% year-over-year.
  • Adjusted EBITDA was $0.4 million, compared to $0.5 million in Q3-2025.
  • Cash flow from operations was $0.6 million, raising the end-of-quarter cash balance to over $3.5 million.
  • CEO Ilan Danieli stated the company is well-positioned to accelerate commercialization of its product portfolio using its strong cash position.
  • A shareholder call to discuss performance will be held today at 5 PM ET.
  • The company focuses on cancer diagnostics to improve accuracy, reduce misdiagnoses, & lower healthcare expenses.
  • The press release includes forward-looking statements regarding future growth, financial targets, & potential risks.
Company
Precipio, Inc.
Keywords
Nasdaq:PRPO, Precipio, Inc.